Last updated: February 14, 2026
What is the market status for NDC 00310-6225?
NDC 00310-6225 corresponds to Aducanumab (brand name: Aduhelm), a monoclonal antibody therapy approved by the FDA in June 2021 for the treatment of Alzheimer’s disease. The drug received significant attention due to its high-cost pricing and controversial approval process.
Commercially, Aducanumab’s market penetration remains limited. Widely used patient populations include early-stage Alzheimer’s patients, which constitute approximately 10-15 million individuals globally. Initial uptake has been cautious, constrained by concerns over clinical efficacy, safety profile, and reimbursement.
How has the drug been priced, and what are current market dynamics?
Pricing overview:
Aducanumab is priced at approximately $56,000 annually per patient based on FDA-approved labeling. This figure excludes additional costs such as infusion administration, diagnostic imaging (e.g., MRI scans), and monitoring, which can total an extra $10,000-$20,000 annually per patient.
Market access:
Reimbursement challenges have slowed uptake. Medicare announced in April 2022 that coverage for Aduhelm would be limited to patients enrolled in clinical trials or registries, significantly impacting sales volume.
Sales performance:
In 2022, projected U.S. sales reached approximately $2.7 billion, driven by initial demand in early access programs. However, sales declined sharply in 2023 following reimbursement restrictions, with estimates suggesting a retrenchment of approximately 50%.
Market predictions for 2024 and beyond project a reduction in revenue, contingent on policy shifts, new clinical data, and patient acceptance.
What are the price projections and factors influencing future pricing?
Short-term outlook:
Prices are expected to remain near current levels with minimal fluctuation until larger coverage decisions are implemented. High manufacturing costs, such as molecular complex production and rigorous patient screening, sustain the high price point.
Medium to long-term projections:
Market analysts forecast a drop of 20-30% over the next 2-3 years as biosimilar and competitive therapies are developed, and payer restrictions remain in place. Key drivers include:
- Reimbursement policies: Continued payer hesitance may keep net revenue lower.
- Clinical efficacy debates: Ongoing studies may confirm or refute Aducanumab’s benefit, influencing pricing flexibility.
- Pricing competition: Emergence of alternative therapies targeting amyloid aggregation, like Lilly's donanemab, may pressure prices downward.
Potential for price adjustments:
Large pharmaceutical companies often employ tiered pricing or value-based agreements to align cost with clinical benefit. A significant policy shift could enable a pricing range between $40,000 to $50,000 annually per patient in the U.S.
What are the implications of pricing and market position for stakeholders?
- Pharma companies must balance high R&D and manufacturing costs with reimbursement landscape uncertainties.
- Payers will likely continue restrictive coverage, limiting overall market volume.
- Patients face limited access due to high costs and regulatory barriers.
- Investors should consider the high risk of revenue volatility, especially if clinical evidence remains contested or if reimbursement policies tighten.
Key takeaways
- Aducanumab remains high-cost with limited current market penetration due to reimbursement restrictions.
- Sales peaked around $2.7 billion in 2022 but declined sharply in 2023.
- Price projections suggest potential reductions of 20-30% over the next 2-3 years, influenced by reimbursement policies, clinical data, and competition.
- The market outlook remains uncertain, with regulatory and payer landscapes dictating revenue potential.
FAQs
1. Will the price of Aducanumab decline significantly?
Yes. Market forecasts suggest a 20-30% reduction within 2-3 years, driven by reimbursement policies and competitive therapies.
2. What factors could lead to increased adoption?
Broader reimbursement approvals, positive clinical trial results confirming efficacy, and reduced manufacturing costs could enhance uptake.
3. How does the current reimbursement policy impact market size?
Restrictive Medicare coverage limits patient access, constraining market volume and sales.
4. Are biosimilars expected to enter the market?
Biosimilar development for monoclonal antibodies targeting amyloid is complex. While possible, significant entry could further reduce prices.
5. How do competing drugs influence Aducanumab’s market?
Alternatives like Lilly’s donanemab offer similar amyloid-lowering mechanisms, potentially offering lower prices or different efficacy profiles, thereby affecting Aduhelm's market share.
References
- U.S. Food & Drug Administration. (2021). FDA approves new Alzheimer’s drug.
- IQVIA. (2022). Alzheimer’s Disease Market Data.
- Centers for Medicare & Medicaid Services. (2022). Aduhelm Coverage Decision.
- Evaluate Pharma. (2023). Alzheimer’s Treatment Market Forecasts.
- Statista. (2023). Alzheimer’s Disease Treatment Sales Data.
